Background Uveal melanoma is a disease that is distinct from cutaneous melanoma, with a
low tumor mutational burden and a 1-year overall survival of approximately 50% in patients …

Background Tebentafusp, a T-cell receptor–bispecific molecule that targets glycoprotein 100
and CD3, is approved for adult patients who are positive for HLA-A* 02: 01 and have …

Metastatic disease from uveal melanoma occurs in almost 50% of patients suffering from this
ocular tumour, with median survival from development of symptoms being around 1 year. In …

In patients with previously treated metastatic uveal melanoma, the historical 1 year overall
survival rate is 37% with a median overall survival of 7.8 months. We conducted a …

PURPOSE This phase I study aimed to define the recommended phase II dose (RP2D) of
tebentafusp, a first-in-class T-cell receptor/anti-CD3 bispecific protein, using a three-week …

Tebentafusp (tebentafusp-tebn; Kimmtrak®) is a first-in-class, bispecific gp100 peptide-HLA-
A* 02: 01 directed T cell receptor (TCR) CD3 T cell engager being developed by …

Background Distinct systemic treatments exist for metastatic uveal melanoma. Tebentafusp
and combined immune checkpoint blockade (ICB) with ipilimumab plus anti-PD-1 antibodies …

Tebentafusp is a first-in-class immunotherapy agent that comprises an engineered T-cell
receptor targeting a gp100 epitope presented by human leukocyte antigen-A* 02: 01 cells …

Introduction Metastatic uveal melanoma is associated with poor prognosis and few treatment
options. Tebentafusp recently became the first FDA-approved agent for metastatic uveal …

Purpose: Tebentafusp is a first-in-class bispecific fusion protein designed to target gp100 (a
melanoma-associated antigen) through a high affinity T-cell receptor (TCR) binding domain …